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Objectives The aim of our study was to determine the origin of collagen in the progression of myocardial fibrosis in human
adult transplanted hearts.
Background Changes in the cardiac interstitial collagen network are thought to contribute to abnormal stiffness and function
of the myocardium. The origin of fibrosis-mediating fibroblasts remains incompletely understood, and conflicting
data from animal models suggest that they are either derived intracardially or immigrate from extracardiac
sources.
Methods We studied endomyocardial biopsy specimens from 7 sex-mismatched (female donor heart to a male recipient)
heart transplant recipients by a combination of chromogen in situ hybridization using probes specific for Y chro-
mosomes with immunohistochemistry. On the basis of differences in genetic polymorphisms in the type III colla-
gen gene between donor and recipient tissue, we quantitatively determined origin-specific type III collagen gene
expression in fibrotic areas containing fibroblasts of putative extracardiac origin.
Results In areas of increased cardiac fibrosis years after heart transplantation, a substantial number of Y chromosome–
positive spindle-shaped cells with a fibroblast-like appearance were detected. Many of these cells were identified
as macrophages, and measurement of origin-specific type III collagen synthesis identified cells of intracardiac
origin as the main source for collagen turnover in human cardiac fibrosis.
Conclusions Our data suggest that, in human myocardium, cardiac fibrosis due to chronic allograft rejection up to 15 years
after transplantation or scar formation provoked by mechanical trauma is mainly driven by fibroblasts of intra-
cardiac origin. Antifibrotic treatment strategies, therefore, should target molecular mechanisms that induce fi-
brillogenesis of cells with intracardiac origin. (J Am Coll Cardiol 2012;59:1008–16) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.036Cardiac fibrosis is a common consequence of several path-
ological causes, including ischemia, inflammation, and ep-
isodes of cardiac rejection in transplanted hearts. The
morphological changes of fibrosis are accompanied by in-
creased stiffness of the heart and diminished contractility
that lead to impairment of cardiac performance (1). On a
molecular level, fibrosis is associated with a disruption in
the context of the extracellular matrix and deposition of
extracellular collagen. Fibroblasts are considered to be the
major cellular mediators of these structural changes in the
extracellular matrix architecture (2). However, the origin of
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22, 2011, accepted November 29, 2011.these interstitial cells in the adult myocardium remains
incompletely understood, and data are primarily derived
from animal studies. Traditionally, it was assumed that
fibroblasts in postnatal hearts were directly derived from
embryonic mesenchymal cells and that the increase in the
number of these cells is solely a result of proliferation of
resident fibroblasts (3,4). However, this assumption has
been challenged by the discovery that epithelial cells may
transform into fibroblasts, a process called epithelial–
mesenchymal transition (5). Moreover, in experimental
animal models, it was demonstrated that extracardiac circu-
lating progenitor cells can differentiate toward fibroblasts,
thereby substantially contributing to intracardiac fibroblasts
(6–8). Understanding the origin of fibroblasts in human
myocardium and to what extent they contribute to cardiac
fibrosis, may pave the way to future antifibrotic treatment
strategies (9,10). Our study allowed us to detect the origin
of collagen synthesis in human adult transplanted hearts. In
contrast to previous studies (6–8) that either used animal
models and/or genetically modified cells, we investigated
transplanted human adult myocardium and used differences
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type III gene to study the origin of collagen-producing cells
(11). We quantified the origin of type III collagen under
different pathological conditions: cardiac fibrosis caused by
chronic allograft rejection up to 15 years after heart trans-
plantation and areas of fibrosis caused by acute mechanical
trauma. To our knowledge, we reveal for the first time the
origin of collagen synthesis that is the major component of
cardiac fibrosis in human adult hearts.
Methods
Patients and endomyocardial biopsies. Endomyocardial
biopsy (EMB) results from 7 male patients who had
received a female cardiac allograft during the years 1988 to
2008 were retrieved from the files of the Institute of
Pathology, Medical University of Graz. The EMBs for
monitoring rejection episodes had been performed either as
routine biopsies or as biopsies taken when rejection episodes
in the graft were suspected. The patients were maintained
on a standard triple immunosuppression regimen (cyclo-
sporine, azathioprine, and prednisolone), and rejection ep-
isodes assessed according to the International Society for
Heart and Lung Transplantation were treated with pulse
therapy of cortisone (500 mg daily for 3 days) or
muromonabl-CD3 (OKT3), depending on the duration
and severity of rejection and response to treatment. For
each patient, we selected 4 biopsy specimens that showed
histological signs of chronic allograft rejection in the
transplanted heart. In addition, we explored origin-
specific collagen type III synthesis in 6 biopsy specimens
at 10 to 15 years after transplantation and selected 2 areas
in each patient where an acute mechanical trauma (i.e.,
site of rebiopsy) had induced substantial cardiac scar
formation.
Chromogenic in situ hybridization combined with CD68
immunohistochemistry. To identify whether recipient-
derived fibroblasts populate areas showing signs of in-
creased cardiac fibrosis, we selected samples based on the
criteria mentioned earlier for Y chromosome– directed
chromogenic in situ hybridization (CISH) analysis. De-
tails of procedures and description of controls are pro-
vided in the Online Appendix. A conventional bright-
field microscope was used to analyze the Y chromosome
signals in different cell populations. Cell types were
evaluated by using light microscopy for: 1) morphological
eatures of the cell nuclei; 2) Y chromosome–positive
staining as an indicator for recipient origin; and
3) CD68-positive cells. A cell was defined as Y chromo-
some positive if a punctate, dark-brown signal was
localized within its blue-stained nucleus.
Immunohistochemical analysis of collagen type I and III
and CD68. For assessment of the presence and the amount
of collagen deposition as well as CD68-positive macro-
phages in EMBs, immunohistochemical detection of collagentype I and III and CD68 was
performed in sequentially cut heart
sections. (Details are described in
the Online Appendix.)
Desoxyribonucleic acid isolation
and genotyping of type III col-
lagen. For determination of the ge-
notypes of exon 30 (a single base
substitution from guanine to ade-
nine, rs1800255) and exon 32 (a
single base substitution from cyto-
sine to thymine, rs1801184) of the
collagen type 3 alpha 1 (COL3A1)
gene, we followed restriction frag-
ment length polymorphism proto-
cols as described in detail in the
online Appendix. To determine
the sensitivity and precision of the
method, we performed dilution ex-
periments by mixing deoxyribonu-
cleic acid (DNA) from all genotype combinations with regard to
the marker SNPs at 50:50%, 90:10%, 95:5%%, 99:1%, and
99.9:0.1% mixtures.
Ribonucleic acid isolation and origin-specific collagen
type III expression. The marker SNPs of exon 30 and
exon 32 of the COL3A1 gene from all 7 donor hearts and
their corresponding recipient tissue were initially genotyped
to determine differences in the donor and recipient collagen
type III marker SNPs. In these patients, in whom the
COL3A1 gene can be distinguished from recipients and the
respective donor by the combination of at least 1 allele that
is distinctive (thus enabling origin-specific detection of
COL3A1 expression), we microdissected fibrotic areas of
EMBs from each patient selected according to the criteria
mentioned earlier. Details of procedures and control criteria
for real-time polymerase chain reactions are detailed in the
online Appendix. Reverse transcription was performed us-
ing the SuperScript II Reverse Transcriptase kit (Invitrogen
GmbH, Lofer, Austria). For determination of the origin of
the collagen type III messenger ribonucleic acid (mRNA),
we used a primer extension and SNaPshot Multiplex Kit
(Applied Biosystems, Vienna, Austria) as described in the
online Appendix. Finally, labeled products were run on an
ABI 3100xl capillary sequencer, and peak-heights of signals
were measured using GeneMapper version 3.7 software
(Applied Biosystems, Foster City, California).
Results
A detailed overview regarding the patients’ characteristics
and cardiovascular parameters 10 years after heart transplan-
tation are shown in Tables 1 and 2. To determine whether
extracardiac progenitor cells lead to fibroblast cell chimerism
in transplanted human hearts, we performed CISH analysis
to detect Y chromosomes in biopsies of microscopically
Abbreviations
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hybridization
COL3A1  collagen type 3
alpha 1
DNA  desoxyribonucleic
acid
EMB  endomyocardial
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endoMT  endothelial–
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mRNA  messenger
ribonucleic acid
RNA  ribonucleic acid
SNP  single-nucleotide
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TGF  transforming growth
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Cardiac Fibrosis Is of Intracardiac Origin March 13, 2012:1008–16type I and III deposition (Fig. 1) selected according to the
criteria described in the Methods section. Among the
sex-mismatched transplant patients, Y chromosomes were
detected in some nuclei of cardiomyocytes and endothelial
cells in all samples. However, chimerism was rare, and only
0.5% of all cardiomyocytes were Y chromosome–positive
cells. In areas of increased collagen deposition (Figs. 2A and
2D), we analyzed sequentially cut heart sections and stained
Patient and Biopsy Specimen Characteristics in Which Both CISHCollagen Type III Origin Measuremen s Were PerformedTable 1 Patient and Biopsy Sp imen Characteristics in WhichCollagen Type III Origin Measurements Were Performe
Patient #
Reason
for HTx
Age at
HTx (yrs)
Interval to
Biopsy (yrs)
Acute Rejection in
Current Biopsy (ISHLT
1 IHD 52 1 1A
4 1A
8 1A (site of rebiopsy)
9 1B
10 1A
12 0
13 0 (site of rebiopsy)
14 0
2 DCM 52 1 1A
4 3B
8 0 (site of rebiopsy)
9 1A
10 1B
11 0 (site of rebiopsy)
3 DCM 67 1 1B
3 1A
5 0 (site of rebiopsy)
6 1A (site of rebiopsy)
7 1A
9 0
4 DCM 64 1 1A
4 3A
7 1B
10 0 (site of rebiopsy)
11 1A
12 0 (site of rebiopsy)
5 DCM 57 1 1A
4 1B
9 0 (site of rebiopsy)
10 1B
11 1A
12 1A (site of rebiopsy)
13 1A
14 0
6 DCM 43 1 1B
4 3B
10 0 (site of rebiopsy)
11 1A
13 0 (site of rebiopsy)
14 1A
14 0
15 0
7 DCM 17 Not analyzed No differences in collagen ge
CISH  chromogen in situ hybridization; DCM  dilated cardiomyopathy; HTx  heart transplantafor CD68-positive macrophages (Figs. 2B and 2E) followed (y the Y chromosome–directed CISH technique (Figs. 2C
nd 2F). In fibrotic areas (Fig. 2A), where only a sparse
nfiltrate of macrophages was visible (Fig. 2B), nearly all
void- to spindle-shaped putative fibroblasts were Y chro-
osome negative (Fig. 2C) and thus of donor (intracardiac)
rigin. In contrast, areas of fibrosis (Fig. 2D) containing a
igh number of CD68-positive macrophages (Fig. 2E)
howed cells with ovoid Y chromosome–positive nuclei
sis andCISH Analysis and
Documented Severe
Rejection (ISHLT >3)
Episodes at 10 Yrs
Post-HTx Post-Transplantation Graft Survival (yrs)
0 Alive, 14 yrs post-transplantation
1 Alive, 11 yrs post-transplantation
0 Dead due to graft failure, 9 yrs post-transplantation
1 Dead due to graft failure, 12 yrs post-transplantation
0 Alive, 14 yrs post-transplantation
3 Dead due to graft failure, 19 yrs post-transplantation
Alive, 13 yrs post-transplantation
D  ischemic heart disease; ISHLT  International Society for Heart and Lung Transplantation.AnalyBoth
d
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March 13, 2012:1008–16 Cardiac Fibrosis Is of Intracardiac Originidentified many of these cells as Y chromosome and CD68-
positive macrophages (Fig. 3A), whereas ovoid- to spindle-
shaped, CD68, and Y chromosome–negative cells represent
donor-derived fibroblasts (Fig. 3B). Table 3 provides an
overview of the number and percentages of positive cells in
each patient.
For determination of whether and to what extent fibro-
blasts of putative extracardiac origin contribute to cardiac
fibrosis, we developed a strategy to detect origin-specific
fibrosis (Fig. 4). In our white sample collection, the fre-
quency of the G allele was 0.71, and the frequency of the A
allele was 0.29 for exon 30; the frequency of the T allele was
0.82, and the frequency of the C allele was 0.18 for exon 32.
In 6 of the 7 patients, the genotypes between donor and
recipient tissue showed at least 1 distinctive allele (Table 4).
For further COL3A1 expression analysis, we included only
these 6 patients for whom at least 1 allele differed between
donor and recipient tissue. For technical reasons, it was
necessary to establish a correction factor derived from
genomic DNA, in which the ratio of alleles is known to be
equimolar (11). For each individual genotype combination,
we measured the genomic ratios of the A and G alleles and
the T and C alleles. Dilution experiments showed that,
depending on the genotype, 0.5% to 5% of recipient-derived
nucleic acids are reproducibly quantifiable by using this
technique in the background of the dominating allele
(Table 4). Overall, 48 biopsy specimens were analyzed for
Cardiovascular Parameters 10 (1) Years Post-TransplantationTable 2 Cardiovascular Parameters 10 (1) Years Post-Transp
Patient # NYHA Class (1–4) TR (0–3) LVEF (%) LV
1 2 1 56
2 1 1 67
3 2 2 49
4 2 2 69
5 1 1 65
6 2 2 69
7 1 0 61
DD  diastolic dysfunction determined according to transmitral blood flow; IVS  end-diastolic
end-diastolic diameter; NYHA  New York Heart Association; TR  tricuspid regurgitation (0  no
Figure 1 Immunohistochemical Analysis of an Area of Increase
(A) Collagen type I deposition and (B) collagen type III deposition. Specific antibo
cell nuclei are counterstained by blue hematoxylin.rigin-specific COL3A1 mRNA expression (Online Table 1).
one of the 24 biopsy specimens showing increased fibrosis
rom chronic rejection, the 6 specimens harvested 10 to 15
ears after heart transplantation, the 6 specimens harvested
etween day 3 and day 30 after transplantation, or the 12
pecimens showing scar formation after acute mechanical
rauma (i.e., site of rebiopsy) indicated any detectable level
f COL3A1 mRNA from extracardiac origin (Fig. 5), with
theoretically 0.1% detection limit for the assay. (For
etails, see the Online Appendix.)
In an attempt to investigate whether macrophages influ-
nce the number of extracardiac fibroblasts in areas of
ardiac fibrosis or induce collagen synthesis of cells with
ecipient origin, we analyzed areas of fibrosis that showed
igh numbers of CD68-positive macrophages (Fig. 2E) and
ompared them with areas of fibrosis containing only a few
umbers of macrophages (Fig. 2B). We found no differ-
nces in the number of recipient-derived fibroblasts or in the
mount of recipient-derived collagen synthesis.
iscussion
enerally, the pool of cardiac fibroblasts may be recruited
rom different sources. Traditionally, there is a well-defined
essile intracardiac fibroblastic cell population consisting of
broblasts that only proliferate after receiving an activating
timulus. Undifferentiated intracardiac fibroblastic progen-
tion
m) DD (1-4) IVS (mm) Hypertension (>140/90 mm Hg)
1 16 Yes
1 9 No
2 15 Yes
2 14 Yes
1 12 Yes
2 17 Yes
1 12 No
er of intraventricular septum; LVEF  left ventricular ejection fraction; LVEDD  left ventricular
mild, 2  moderate, and 3  severe).
rosis
corating collagen fibers are visualized by a red chromogen;lanta
EDD (m
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Cardiac Fibrosis Is of Intracardiac Origin March 13, 2012:1008–16itor cells are present in normal newborn and adult hearts,
but their differentiation fate and role in cardiac fibrosis are
poorly understood (12). It has been shown that, similar to
the embryonic developmental concept, a mechanism in
which endothelial cells may emigrate and transform into
intracardiac fibroblasts might represent an important source
of intracardiac fibroblasts (5). Another potential source of
fibrosis-mediating fibroblasts might be extracardiac progen-
itor cells that emigrate from the circulation to different
organs and substantially contribute to organ fibrosis under
pathological conditions (13,14). In this study, we examined
Figure 2 Sequentially Cut Heart Sections Showing Areas of Inc
Immunohistochemical (red) staining for collagen (A, D), CD68 staining with a red
show higher magnifications of Y chromosome–positive nuclei, indicated by an arro
vessel (v), and D to F show surrounding cardiomyocytes (m). In areas of (A) increased
CD68-positive cells), most ovoid- to spindle-shaped cells are Y chromosome negative;
inset of C indicates a single Y chromosome–positive cell. In contrast, in areas of (D)
E indicate CD68-positive cells), many of the ovoid- to spindle-shaped cells show Y chrwhether fibroblasts of extracardiac origin are enriched infibrotic areas caused by different pathological conditions in
human cardiac allografts. For this purpose, we first followed
a strategy to detect fibroblasts with putative extracardiac
origin in human transplanted hearts by studying cell chime-
rism in a model of sex-mismatched cardiac transplantation.
Based on this model, Minami et al. (15) demonstrated a
high degree of chimerism for different nonmyocytic cardiac
cell types (e.g., endothelial cells with up to 24% originating
from extracardiac sources 1 month after transplantation).
One major obstacle for studying fibroblast cell chimerism, as
stated by Minami et al. (15), is that no specific antibody for
d Fibrosis
ogen (B, E) and Y-chromosome in situ hybridization (C, F). Insets below C and F
punctate brown signal within the nucleus. A to C contain a longitudinally cut blood
is that showed sparse staining of CD68-positive macrophages (arrows in B indicate
they are donor derived and most likely represent fibroblasts. An arrow in the right
ed fibrosis showing abundant infiltrations of CD68-positive macrophages (arrows in
me–positive nuclei (arrows in insets below F).rease
chrom
w as a
fibros
thus,
increas
omosoformalin fixed paraffin embedded tissue exists that can
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March 13, 2012:1008–16 Cardiac Fibrosis Is of Intracardiac Originreliably detect fibroblasts. In our study, we chose to use
CISH technology, which allows for simultaneous observa-
tion of tissue morphology and Y chromosome signals. By
immunohistochemically preselecting areas with prominent
collagen type I and III protein deposition, we encountered
a substantial number of cells with a spindle-shaped
fibroblast-like phenotype that displayed a positive signal for
the Y chromosome. However, combining CISH analysis
with immunohistochemical staining for the CD68 antigen
demonstrated that many of these fibroblasts with putative
extracardiac origin were in fact inflammatory macrophages.
In areas of fibrosis, where we excluded the presence of
macrophages by a negative selection of CD68 staining, the
vast majority of cells of putative fibroblastic phenotype were
Y chromosome–negative cells. Activated macrophages have
been previously implicated to cause incorrect chimerism
results because they may express some markers typical for
cardiomyocytes or fibroblasts (16). In this context, it should
be mentioned that under some conditions, monocyte-
derived, collagen-synthesizing fibrocytes might also express
Figure 3 Combined Y Chromosome CISH Analysis With Immuno
In an area of increased fibrosis, ovoid- to spindle-shaped nucleus shows a puncta
male recipient–derived macrophage. (A) Multiple ovoid- to spindle-shaped, CD68-n
(B). CISH  chromogen in situ hybridization.
Counting of Y Chromosome–Positive/NegativeSpindle- t Ovoid-Shaped Nuclei in Areas ofIncreased Fibr sis
Table 3
C unting of Y Chromosome–Positive/Negative
Spindle- to Ovoid-Shaped Nuclei in Areas of
Increased Fibrosis
Patient #
Y Chromosome
CISH Staining
Combined Y Chromosome/
CD68 Staining
No. (%) of Y Chromosome–Positive/
Y Chromosome–Negative
Spindle- to Ovoid-Shaped Nuclei
No. of Y Chromosome–Positive
CD68-Positive Cells/
Y Chromosome–Positive
CD68 Negative Cells/
Y Chromosome–Negative
CD68-Negative Cells
1 41/610 (6.7) 31/2/510
2 52/480 (10.8) 41/0/460
3 61/750 (8.1) 37/3/520
4 15/630 (2.3) 28/2/410
5 31/680 (4.5) 19/1/490
6 83/560 (14.8) 33/3/550
7 68/800 (8.5) 49/4/550CISH  chromogen in situ hybridization.CD68 (17). Previously published studies have reported
controversial results regarding the proportion of fibroblasts
of extracardiac origin in cardiac fibrosis under different
pathological conditions. For instance, Wu et al. (7) reported
that up to 65% of fibroblasts were of recipient origin in a rat
model of chronic allograft rejection and that circulating
recipient-derived mesenchymal stem cells may substantially
repopulate intracardiac fibroblasts (6). In mice at 3 to 12
months after bone marrow transplantation, Visconti and
Markwald (8) demonstrated that hematopoietic stem cell–
derived cells contribute to fibroblast formation under nor-
mal (nonpathological) conditions. The same researchers also
found that periostin plays an essential role in directing the
differentiation of progenitor cells to mature into fibroblasts
(12). Furthermore, Möllmann et al. (18) reported a bone
marrow–derived fibroblast content of 24% at 7 days and
28% at 21 days after myocardial infarction in the myocar-
dium of a transgenic mouse model. In a murine model of
nonadaptive fibrosis, Haudek et al. (19) reported that
ischemic cardiomyopathy is associated with monocyte che-
moattractant protein-1 driven uptake of bone marrow–
derived blood-borne fibroblast precursors of hematopoietic
origin.
In contrast to these studies that show a substantial
proportion of fibroblasts with extracardiac origin, Zeisberg
et al. (5), who used a genetically engineered mouse model,
demonstrated that only 13.4% of FSP1-positive (a marker
for fibroblastic differentiation) cells originated from circu-
lating bone marrow–derived cells in hearts subjected to
pressure overload by aortic constriction. In unbanded con-
trol hearts, the authors did not detect any FSP1-positive
cells of bone marrow origin. In another murine model for
myocardial infarction, Yano et al. (20) found only a few
vimentin-positive putative fibroblasts of bone marrow origin
at 7 days post-coronary artery occlusion. The reasons for
these discrepancies are not known; however, they may be
due to differences in fibrosis-mediating triggers, use of
chemical Staining for CD68
n signal in the nucleus (arrow) and red staining for CD68, thus indicating a
e, and Y chromosome–negative nuclei are visible in this area of cardiac fibrosishisto
te brow
egativgenetically modified cells, the timing of the observations,
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methods for identifying fibroblasts. In addition, the use of
immunosuppressive agents in human patients could con-
tribute to the observed discrepancy. Whether and which of
these experimental animal models sufficiently reflect the
Figure 4 Strategy for Determining the Origin-Specific Type III C
Differences of single-nucleotide polymorphisms (SNPs) in the coding region of the
the measurement of recipient and donor-derived collagen III messenger ribonucleic
Allele Constitution at 2 Loci of theCOL3A1 Gene in Donor and Recipient TissuesTable 4 Allele Constituti n at 2 Loci of theCOL3A1 Gene in Donor and Recipient Tissues
Sample Identification
COL3A1 rs1800255
(Exon 30 G>A)
COL3A1 rs1801184
(Exon 32 T>C)
Recipient 1 G/G T/T (5%)
Donor 1 G/G C/T
Recipient 2 G/A (0.5%) T/T
Donor 2 A/A T/T
Recipient 3 G/A (2.5%) T/T
Donor 3 G/G T/T
Recipient 4 G/A (2.5%) T/T (5%)
Donor 4 G/G C/T
Recipient 5 G/A (2.5%) T/T (2.5%)
Donor 5 G/G C/C
Recipient 6 G/A C/T (2.5%)
Donor 6 G/A T/T
Recipient 7 G/G T/T
Donor 7 G/G T/T
All recipients except Patient #7 can be distinguished from the respective donor by the combination
of at least 1 allele that is distinctive, thus, enabling origin-specific detection of collage type 3 alpha
1 (COL3A1) expression. The limits of detection for each possible allele combination obtained from
serial dilution experiments are depicted in parentheses.human situation remains unclear. Thus, the aim of our
study was not only to identify the phenotype of fibroblasts
with putative extracardiac origin but also to determine
whether and to what extent these fibroblasts have an active
functional role in the development of cardiac fibrosis in
human hearts.
Collagen type III represents one of the major constituents
of cardiac fibrosis, and cardiac fibroblasts are the predomi-
nant collagen producers in the heart (21). The serum
concentration of the propeptide of type III procollagen has
been used as a marker for allograft rejection because collagen
type III synthesis reflects wound healing and collagen
turnover after rejection episodes (22). Therefore, we mea-
sured origin-specific collagen type III synthesis under dif-
ferent pathological conditions. For the purpose of detecting
and quantifying origin-specific collagen synthesis, we
adapted a technique that has been used previously to
quantify allelic expression imbalances (23). The use of 2
marker SNPs that are part of the coding sequence of
COL3A1 mRNA enabled us to quantify origin-specific
type III collagen. Based on differences in the marker SNPs
between donor and recipient collagen, we measured the
origin-specific COL3A1 mRNA expression in myocardial
tissue with increased cardiac fibrosis. Interestingly, in all
samples that we tested, we could only detect COL3A1
en Expression in Transplanted Hearts
en III gene enable
(mRNA) expression.ollag
collag
acidmRNA of donor origin. These data suggest that, in contrast
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intracardiac origin that are either pre-existing or generated
by endothelial–mesenchymal transition (endoMT) are the
main source of collagen in cardiac fibrosis in human cardiac
allografts. We observed no evidence of type III collagen
synthesis from extracardiac origin, up to 15 years after
cardiac transplantation or in areas with increased content of
inflammatory cells. It therefore seems implausible that
circulating cells substantially contribute to remodeling or
normal collagen homeostasis in the human adult heart.
Study limitations. A potential limitation of our study is
the relative small sample size, especially with regard to
biopsies conducted early after transplantation. Early onset of
fibrosis by fibroblasts of extracardiac origin was not sup-
ported by our study. However, as the majority of our biopsy
specimens were obtained relatively late after transplantation,
the small sample size in the “early” subset of biopsies does
not allow us to completely rule out this possibility.
Currently, there is no therapy available that reverses
cardiac fibrosis once significant amounts of collagen have
been deposited. Thus, there is paramount interest to target
its source: the cardiac fibroblast. Our study identified that
the majority of cardiac collagen is synthesized by fibroblasts
of intracardiac origin. Previous studies reported that a
Figure 5 Determination of Origin-Specific
COL3A1 mRNA Using the SNaPshot Assay
(A) A positive control from a heterozygous sample in which both alleles
(G allele in blue and A allele in green from exon 30) are present in equimolar
amounts. For technical reasons, the alleles show peaks with slightly different
heights (29). Due to the influence of the dye on the mobility of the desoxyribo-
nucleic acid fragment, the alleles show no exact overlap. (B) Representative
data from analysis of collagen type III expression in donor heart of patient 3.
Only peaks in blue color, representing G allele from donor-derived collagen,
were detected in all biopsy specimens analyzed (yellow peak represents an
internal size marker of the GeneScan 120 LIZ size standard [ABI]). COL3A1 
collagen type 3 alpha 1; mRNA  messenger ribonucleic acid.substantial part of intracardiac fibroblasts—especially indiseased conditions such as pressure overload hypertrophy,
failure, or graft versus host reaction—can be derived by
endoMT (5,24). Thus, interfering with endoMT may open
new therapeutic avenues to prevent cardiac fibrillogenesis.
Transforming growth factor (TGF)-beta signaling, both
with its canonical (SMADs) and noncanonical (e.g., MEK,
p38-MAPK, PI3K, TAK1) pathways, plays an important
role in the process of endoMT, the fibroblast-to-
myofibroblast transition, and in adverse fibrotic remodeling
in general (25–30). For instance, inhibition of SMAD3,
either by small molecule inhibitors or transgenic mouse
models, modulates endoMT; BMP7 prevents endoMT and
is itself modulated by TAK1 (24,26,27,31). Although these
interventions are still only used in basic research, TGF-beta
inhibition through anti–TGF-beta antibodies is already
under investigation in clinical trials for a variety of diseases.
Interestingly, there is also a cross-talk between atrial natri-
uretic peptide/cyclic guanosine monophosphate/protein ki-
nase G and TGF-beta signaling, in which protein kinase G
phosphorylates SMAD3 on 2 sites that are distinct from the
TGF-beta receptor kinase phosphorylation sites, thereby
inhibiting nuclear translocation of pSMAD3 (32). This is
intriguing, as PDE5a inhibition is currently evaluated for
diastolic dysfunction and is an established therapy for
pulmonary hypertension, both conditions that are frequently
encountered in patients after heart transplantation (33,34).
Conclusions
Although we cannot exclude the possibility that fibroblast
cell chimerism might occur to a limited extent in the
transplanted human myocardium, the functional contribu-
tion of cells with extracardiac origin to cardiac fibrosis is
minimal or absent in chronic allograft rejection up to 15
years after transplantation. According to our data, cardiac
chimerism of fibroblasts is not associated with chronic graft
failure. These data refute the hypotheses derived from some
animal studies. Therefore, therapeutic approaches for inhib-
iting cardiac allograft fibrosis and remodeling of the heart
should target mechanisms that stimulate intracardiac fibril-
logenesis rather than mechanisms which restrict the immi-
gration of circulating fibroblastic progenitor cells to the
myocardium.
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